Next Article in Journal
Cancer Cell Fusion: Mechanisms Slowly Unravel
Next Article in Special Issue
T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome
Previous Article in Journal
Differential Impact of Hyperglycemia in Critically Ill Patients: Significance in Acute Myocardial Infarction but Not in Sepsis?
Previous Article in Special Issue
Astroglial Activation by an Enriched Environment after Transplantation of Mesenchymal Stem Cells Enhances Angiogenesis after Hypoxic-Ischemic Brain Injury

New Phase of Growth for Xenogeneic-Based Bioartificial Organs

Organogenesis Inc., 150 Dan Road, Canton, MA 02021, USA
Academic Editor: Maurizio Muraca
Int. J. Mol. Sci. 2016, 17(9), 1593;
Received: 30 June 2016 / Revised: 17 August 2016 / Accepted: 29 August 2016 / Published: 21 September 2016
(This article belongs to the Special Issue Advances in Cell Transplantation)
In this article, we examine the advanced clinical development of bioartificial organs and describe the challenges to implementing such systems into patient care. The case for bioartificial organs is evident: they are meant to reduce patient morbidity and mortality caused by the persistent shortage of organs available for allotransplantation. The widespread introduction and adoption of bioengineered organs, incorporating cells and tissues derived from either human or animal sources, would help address this shortage. Despite the decades of development, the variety of organs studied and bioengineered, and continuous progress in the field, only two bioengineered systems are currently commercially available: Apligraf® and Dermagraft® are both approved by the FDA to treat diabetic foot ulcers, and Apligraf® is approved to treat venous leg ulcers. Currently, no products based on xenotransplantation have been approved by the FDA. Risk factors include immunological barriers and the potential infectivity of porcine endogenous retrovirus (PERV), which is unique to xenotransplantation. Recent breakthroughs in gene editing may, however, mitigate risks related to PERV. Because of its primary role in interrupting progress in xenotransplantation, we present a risk assessment for PERV infection, and conclude that the formerly high risk has been reduced to a moderate level. Advances in gene editing, and more broadly in the field, may make it more likely than ever before that bioartificial organs will alleviate the suffering of patients with organ failure. View Full-Text
Keywords: bioartificial organs; xenotransplantation; gene editing; clinical trials; risk assessment bioartificial organs; xenotransplantation; gene editing; clinical trials; risk assessment
Show Figures

Graphical abstract

MDPI and ACS Style

Pitkin, Z. New Phase of Growth for Xenogeneic-Based Bioartificial Organs. Int. J. Mol. Sci. 2016, 17, 1593.

AMA Style

Pitkin Z. New Phase of Growth for Xenogeneic-Based Bioartificial Organs. International Journal of Molecular Sciences. 2016; 17(9):1593.

Chicago/Turabian Style

Pitkin, Zorina. 2016. "New Phase of Growth for Xenogeneic-Based Bioartificial Organs" International Journal of Molecular Sciences 17, no. 9: 1593.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop